Micafungin Accord

Micafungin, the active ingredient in Micafungin Accord, is an echinocandin presented as an injectable solution for intravenous use. It treats invasive candidiasis and other Candida infections in adult and pediatric patients.

GNH USA supplies Micafungin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin is an echinocandin antifungal that inhibits fungal cell wall synthesis, primarily used for serious Candida infections. - Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves mucosal infection in immunocompromised individuals. - Prophylaxis of Candida infections: prevents invasive disease in patients undergoing hematopoietic stem cell transplantation.

Common Side Effects: - Fever: transient elevation of body temperature during infusion. - Nausea: mild gastrointestinal discomfort. - Elevated liver enzymes: increase in ALT/AST values. - Headache: mild to moderate headache.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate treatment. - Hepatic dysfunction: significant liver injury with jaundice. - Severe hypotension: marked drop in blood pressure during infusion.

Precautions should be taken to ensure safe administration of Micafungin. - Liver function monitoring: check ALT/AST before and during therapy. - Renal function assessment: evaluate creatinine clearance in patients with kidney impairment. - Hypersensitivity caution: discontinue if signs of allergic reaction appear. - Pediatric dosing consideration: use only under specialist supervision. - Drug interaction review: assess concomitant medications that affect hepatic metabolism. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin may interact with several medications; review is essential. Major Interactions (Avoid): - Cyclosporine: increased micafungin exposure, risk of toxicity. - Rifampin: reduced micafungin concentrations, possible treatment failure. - Strong enzyme inducers (e.g., carbamazepine): lower micafungin levels. Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): potential additive hepatotoxicity. - Warfarin: possible alteration of INR, monitor coagulation.